Objective To explore the therapeutic effect of Tongsaimai Tablets combined with clopidogrel bisulfate in treatment of acute cerebral infarction.Methods Patients(108 cases)with acute cerebral infarction from January 2020 to March 2023 were randomly divided into control(54 cases)and treatment(54 cases)group.Patients in the control group were po administered with Clopidogrel Bisulfate Tablets,75 mg/time,once daily.Patients in the treatment group were po administered with Tongsaimai Tablets on the basis of the control group,5 tablets/time,three times daily.Patients in two groups were treated for 14 d.After treatment,the clinical evaluation was evaluated,and the symptom relief times,the scores of FMA and NIHSS,the levels of IL-6 and Hcy,and adverse reaction in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of patients in the treatment group(98.15%)was significantly higher than that in the control group(83.33%,P<0.05).After treatment,the time of symptom improvement in the treatment group was significantly earlier than that in the control group(P<0.05).After treatment,the NIHSS score in two groups was significantly decreased,while the FMA score was significantly increased(P<0.05),and these scores in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the levels of serum inflammatory factors IL-6 and Hcy in the treatment group were significantly lower than those in the control group(P<0.05),which in the treatment group was significantly lower than that in the control group(P<0.05).After treatment,the incidence of adverse reactions in the treatment group(5.56%)was significantly lower than that in the control group(12.96%,P<0.05).Conclusion The curative effect of clopidogrel bisulfate combined with Tongsaimai Tablets in treatment of acute cerebral infarction is definite,which can effectively improve the clinical symptoms,correct the state of cerebral nerve injury,weaken the inflammatory response and enhance the motor function of patients.
Objective To investigate the clinical efficacy of Rotigotine Patches combined with amantadine in treatment of Parkinson's disease.Methods From November 2019 to December 2021,124 patients with Parkinson's disease admitted to the outpatient and inpatient departments of Bayannur Hospital were selected,and all patients were divided into control group and treatment group by random number table method,with 62 patients in each group.Patients in the control group were po administered with Amantadine Hydrochloride Tablets,0.1 g/time,twice daily.Patients in the treatment group were given Rotigotine Patches on the basis of the control group,applied the product to the skin at the same time every day and keep it for 24 h,the initial dosage was 2 mg/24 h,once daily,and applied to another part of the skin when changing the patch each time,to avoid repeated use within 14 d of the same part.The weekly dosage was increase by 2 mg/24 h until the effective dosage(not more than 8 mg/24 h).The treatment course of both groups was 12 weeks.The clinical efficacy of the two groups was observed.The scores of the unified Parkinson's Disease Rating Scale(UPDRS),the Psychosocial Adaptation Scale(PAS),the Parkinson's Sleep Scale-2(PDSS-2),the eight item Parkinson's Disease Questionnaire(PDQ-8),the Parkinson's Disease Non motor Symptom Scale(PD-NMSS),and the levels of serum superoxide dismutase(SOD),acetylcholine(Ach),and interleukin-6(IL-6)were compared between the two groups before and after treatment.Results After treatment,the effective rate of the treatment group was 93.55%,which was significantly higher than that of the control group(80.65%)(P<0.05).After treatment,the scores of Ⅰ,Ⅱ,Ⅲ,and Ⅳ in UPDRS and the total scores of scales in both groups were significantly decreased compared with those before treatment(P<0.05).The decrease was more significant in the treatment group(P<0.05).After treatment,PAS scores in both groups were significantly increased,while PDSS-2,PDQ-8 and PD-NMSS scores were significantly decreased(P<0.05).The improvement was more significant in the treatment group(P<0.05).After treatment,the serum SOD level in both groups was significantly increased,while the serum Ach and IL-6 levels were significantly decreased(P<0.05).After treatment,the serum SOD level in the treatment group was significantly higher than that in the control group,and the serum Ach and IL-6 levels were significantly lower than that in the control group(P<0.05).Conclusion Rotigotine Patches combined with amantadine can achieve a definite effect in treatment of Parkinson's disease,and can effectively improve the clinical symptoms,sleep status and quality of life of patients,and can further enhance the antioxidant capacity of the body,reduce inflammatory damage and inhibit the hyperactivity of Ach,which is conducive to delaying the progress of the disease with good safety.
Objective To explore the clinical efficacy of Jisheng Shenqi Pills and losartan potassium in treatment of chronic glomerulonephritis.Methods Patients(88 cases)with chronic glomerulonephritis in Suzhou Hospital of Anhui Medical University from January 2019 to February 2023 were randomly divided into control(44 cases)and treatment(44 cases)group.Patients in the control group were po administered with Losartan Potassium Tablets,100 mg/time,once daily.Patients in the treatment group were po administered with Jisheng Shenqi Pills on the basis of the control group,1 pill/time,three times daily.Patients in two groups were treated for 2 months.After treatment,the clinical evaluation was evaluated,and the levels of renal function indicators CysC,NGAL and RBP,the levels of inflammatory indicators IL-6,IFN-γ and TNF-α in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 90.91%,which was significantly higher than that of the control group(75.00%,P<0.05).After treatment,the levels of serum CysC,urinary NGAL,urinary RBP,and serum IL-6,IFN-γ and TNF-α levels in two groups were significantly decreased(P<0.05),and the decrease in the treatment group was significantly higher than that in the control group(P<0.05).Conclusion The combination of Jisheng Shenqi Pills and Losartan Potassium Tablets has good clinical efficacy in the treatment of chronic glomerulonephritis,which can effectively improve the renal function and inflammatory response.
Artificial intelligence algorithms include machine learning algorithms and deep learning algorithms,which can be applied to discover drug targets,discover and optimize lead compounds,determine candidate drugs,and optimize druggability.Artificial intelligence algorithms can achieve model building and high-throughput virtual computing through complex big data system learning.When applied in drug research and development,it can shorten the research and development cycle to a certain extent,reduce input costs,and thereby improve the success rate of research and development.In this article,the research progress of machine learning algorithms and deep learning algorithms applied in drug development was reviewed,in order to provide reference for the further development of the combination of artificial intelligence technology and drug development.
Objective To mine the signals of adverse drug events(ADE)for selinexor based on the FAERS database,and to provide a reference for safe use of drugs in clinical.Methods The reported odds ratio(ROR)and proportional reported ratio(PRR)methods were used to mine selinexor adverse event reports between the second quarter of 2019 and the third quarter of 2023,and the mined signals were classified and statistically analyzed using the Medical Dictionary of Regulatory Activities(MedDRA)preferred system organ classification(SOC)and preferred termy(PT).Results A total of 4 991 adverse event reports involving 19 868 PTs with selinexor as the first suspected drug were retrieved.After computational screening,118 selinexor ADE signals were obtained,involving 16 SOCs.Selinexor ADE signals were basically consistent with the known relevant safety information,and the adverse events were mainly focused on gastrointestinal system diseases,systemic diseases and various reactions at the drug administration site,various types of examinations,metabolic and nutritional diseases.In addition,53 ADE signals not included in the drug specification were detected,such as constipation,fall,drowsiness,and abnormal renal function.Conclusion FAERS-based big data can provide a comprehensive and in-depth analysis of post-marketing adverse reactions of drugs,suggesting that the clinic should pay close attention to the gastrointestinal toxicity,hematological toxicity and risks not mentioned in the instruction manual of selinexor at the early stage of treatment,and take preventive measures so as to ensure the safety of clinical use.
